Vimta Labs Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs has amended its Memorandum of Association by inserting two new clauses (Clause No. 7 and Clause No. 8) under the Main Objects section, following shareholder approval at the 35th Annual General Meeting held on 6th June 2025. The new Clause 7 allows the company to engage in Contract Research and Development (CDMO) activities covering drug discovery, biotechnology, pharmaceuticals, biopharmaceuticals, and life sciences. The new Clause 8 permits research and development of biologics, biosimilars, peptides, and complex generics, including process and product development for manufacturing, formulation, and packaging. The company has clarified that these are the only changes made to the MOA, with no other modifications. This filing accompanies the complete revised copy of the MOA and AOA being submitted to the stock exchanges for records.
This amendment signals a clear strategic expansion of Vimta Labs beyond its traditional testing and analytical services business into the high-growth CDMO and biologics/biosimilars segments. For shareholders, this widens the company's addressable market and could open new long-term revenue streams, though execution and capital requirements for these new verticals will be key things to watch.